Core 2: Patient-derived organoids and tumor slices to study pancreatic cancer resistance
Official title: Core 2: Human Specimen and Organic Core (HSO Core)
Funded at Salk Institute for Biological Studies · NIH-11364242 · Data updated 2026-11-12
A research core at a major cancer institute uses patient-derived organoids and tumor slices to understand why pancreatic cancer resists treatment and to test new drug combinations.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | July 6, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $434,914 |
| NIH project number | 5P01CA265762-04 |
| Project ID | NIH-11364242 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients diagnosed with pancreatic ductal adenocarcinoma whose tumor material can be used to create organoids and tumor slices.
✕Less likely to help
Patients whose tumor material cannot be processed into organoids or who do not receive a responsive model may not benefit.
What this research studies
This core supports multiple projects by providing patient-derived three-dimensional organoids, tumor slices, and co-cultures with stromal cells. Researchers will use these models to profile how pancreatic cancer responds to therapies and to explore combinations that may overcome resistance. The core will also generate organoids from mouse models to compare findings and help validate potential treatments. The work aims to accelerate discovery of effective strategies to improve outcomes for patients with pancreatic ductal adenocarcinoma.
Why it matters
Potential benefit: If successful, the work could identify new treatment combinations that overcome resistance in pancreatic cancer.
How similar studies have gone: Previous organoid-based studies have shown promise in modeling patient-specific drug responses, with ongoing validation needed for widespread clinical use.
Where this research is happening
-
Salk Institute for Biological Studies
La Jolla, United States Active
Researchers
- Principal investigator: Tiriac, Herve — Salk Institute for Biological Studies
- Study coordinator: Tiriac, Herve
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.